C-Reactive Protein-Albumin Ratio (CAR): A More Promising Inflammation-Based Prognostic Marker for Patients Undergoing Curative Hepatectomy for Hepatocellular Carcinoma

References

• Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi:10.1097/CM9.0000000000002108
   PubMed Web of Science ®Google Scholar
• Hirokawa F, Komeda K, Taniguchi K, et al. Is postoperative adjuvant transcatheter arterial infusion therapy effective for patients with hepatocellular carcinoma who underwent hepatectomy? A prospective randomized controlled trial. Ann Surg Oncol. 2020;27(11):4143–4152. doi:10.1245/s10434-020-08699-w
   PubMed Web of Science ®Google Scholar
• Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–1081. doi:10.1093/carcin/bgp127
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Gruber ES, Jomrich G, Kaider A, Gnant M, Sahora K, Schindl M. The prognostic index independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing resection. Ann Surg Oncol. 2020;27(6):2017–2024. doi:10.1245/s10434-019-08161-6
   PubMed Web of Science ®Google Scholar
• Kasymjanova G, MacDonald N, Agulnik JS, et al. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 2010;17(4):52–58. doi:10.3747/co.v17i4.567
   PubMed Web of Science ®Google Scholar
• Shinko D, Diakos CI, Clarke SJ, Charles KA. Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine. Clin Pharmacol Ther. 2017;102(4):599–610. doi:10.1002/cpt.789
   PubMed Web of Science ®Google Scholar
• Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27(3):553–561. doi:10.1111/j.1440-1746.2011.06910.x
   PubMed Web of Science ®Google Scholar
• Cannon NA, Meyer J, Iyengar P, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol. 2015;10(2):280–285. doi:10.1097/JTO.0000000000000399
   PubMed Web of Science ®Google Scholar
• Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013;258(2):301–305. doi:10.1097/SLA.0b013e318297ad6b
   PubMed Web of Science ®Google Scholar
• Kaida T, Nitta H, Kitano Y, et al. Preoperative platelet-to-lymphocyte ratio can predict recurrence beyond the Milan criteria after hepatectomy for patients with hepatocellular carcinoma. Hepatol Res. 2017;47(10):991–999. doi:10.1111/hepr.12835
   PubMed Web of Science ®Google Scholar
• Schobert IT, Savic LJ, Chapiro J, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol. 2020;30(10):5663–5673. doi:10.1007/s00330-020-06931-5
   PubMed Web of Science ®Google Scholar
• Cananzi F, Minerva EM, Samà L, et al. Preoperative monocyte-to-lymphocyte ratio predicts recurrence in gastrointestinal stromal tumors. J Surg Oncol. 2019;119(1):12–20. doi:10.1002/jso.25290
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang K, Zheng H, Zhao X, Xie S, Liu C. Monocyte lymphocyte ratio predicts the new-onset of chronic kidney disease: a cohort study. Clin Chim Acta. 2020;503:181–189. doi:10.1016/j.cca.2019.11.021
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi:10.1158/1078-0432.CCR-14-0442
   PubMed Web of Science ®Google Scholar
• Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31(4):883. doi:10.1007/s12032-014-0883-x
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and Cancer: triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Wiseman MJ. Nutrition and cancer: prevention and survival. Br J Nutr. 2019;122(5):481–487. doi:10.1017/S0007114518002222
   PubMed Web of Science ®Google Scholar
• Mantzorou M, Koutelidakis A, Theocharis S, Giaginis C. Clinical Value of Nutritional Status in Cancer: what is its Impact and how it Affects Disease Progression and Prognosis. Nutr Cancer. 2017;69(8):1151–1176. doi:10.1080/01635581.2017.1367947
   PubMed Web of Science ®Google Scholar
• Pacelli F, Bossola M, Rosa F, Tortorelli AP, Papa V, Doglietto GB. Is malnutrition still a risk factor of postoperative complications in gastric cancer surgery. Clin Nutr. 2008;27(3):398–407. doi:10.1016/j.clnu.2008.03.002
   PubMed Web of Science ®Google Scholar
• Sierzega M, Niekowal B, Kulig J, Popiela T. Nutritional status affects the rate of pancreatic fistula after distal pancreatectomy: a multivariate analysis of 132 patients. J Am Coll Surg. 2007;205(1):52–59. doi:10.1016/j.jamcollsurg.2007.02.077
   PubMed Web of Science ®Google Scholar
• Schwegler I, von Holzen A, Gutzwiller JP, Schlumpf R, Mühlebach S, Stanga Z. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. Br J Surg. 2010;97(1):92–97. doi:10.1002/bjs.6805
   PubMed Web of Science ®Google Scholar
• Abe T, Tashiro H, Kobayashi T, Hattori M, Kuroda S, Ohdan H. Glasgow prognostic score and prognosis after hepatectomy for hepatocellular carcinoma. World J Surg. 2017;41(7):1860–1870. doi:10.1007/s00268-017-3909-7
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633–2641. doi:10.1016/j.ejca.2011.03.028
   PubMed Web of Science ®Google Scholar
• Zhang H, Ren D, Jin X, Wu H. The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis. Cancer Cell Int. 2020;20(1):462. doi:10.1186/s12935-020-01558-4
   PubMed Web of Science ®Google Scholar
• Higgins MI, Martini DJ, Patil DH, et al. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. Cancer. 2021;127(12):1974–1983. doi:10.1002/cncr.33462
   PubMed Web of Science ®Google Scholar
• Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med. 2009;9:30–33. doi:10.7861/clinmedicine.9-1-30
   PubMed Web of Science ®Google Scholar
• Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M, Salluh JIF. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One. 2013;8(3):e59321. doi:10.1371/journal.pone.0059321
   PubMed Web of Science ®Google Scholar
• Shimizu T, Ishizuka M, Suzuki T, et al. The value of the c-reactive protein-to-albumin ratio is useful for predicting survival of patients with Child-Pugh class a undergoing liver resection for hepatocellular carcinoma. World J Surg. 2018;42(7):2218–2226. doi:10.1007/s00268-017-4446-0
   PubMed Web of Science ®Google Scholar
• Oh TK, Choi YR, Cho JY, et al. The high-sensitivity c-reactive protein/albumin ratio predicts long-term oncologic outcomes after curative resection for hepatocellular carcinoma. J Clin Med. 2018;7(6):139. doi:10.3390/jcm7060139
   PubMed Web of Science ®Google Scholar
• Ren Y, Fan X, Chen G, Zhou D, Lin H, Cai X. Preoperative C-reactive protein/albumin ratio to predict mortality and recurrence of patients with hepatocellular carcinoma after curative resection. Med Clin. 2019;153(5):183–190. doi:10.1016/j.medcli.2018.11.010
   PubMed Web of Science ®Google Scholar
• Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015;61(2):526–536. doi:10.1002/hep.27431
   PubMed Web of Science ®Google Scholar
• Pol B, Campan P, Hardwigsen J, Botti G, Pons J, Le Treut YP. Morbidity of major hepatic resections: a 100-case prospective study. Eur J Surg. 1999;165(5):446–453. doi:10.1080/110241599750006686
   PubMedGoogle Scholar
• Mai RY, Lu HZ, Bai T, et al. Artificial neural network model for preoperative prediction of severe liver failure after hemihepatectomy in patients with hepatocellular carcinoma. Surgery. 2020;168(4):643–652. doi:10.1016/j.surg.2020.06.031
   PubMed Web of Science ®Google Scholar
• Chan JC, Chan DL, Diakos CI, et al. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg. 2017;265(3):539–546. doi:10.1097/SLA.0000000000001743
   PubMed Web of Science ®Google Scholar
• Mai R, Bai T, Luo X, Wu G. Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy. BMC Gastroenterol. 2022;22(1):261. doi:10.1186/s12876-022-02328-4
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Pan T, Zhang F, Li F, et al. Shikonin blocks human lung adenocarcinoma cell migration and invasion in the inflammatory microenvironment via the IL‑6/STAT3 signaling pathway. Oncol Rep. 2020;44(3):1049–1063. doi:10.3892/or.2020.7683
   PubMed Web of Science ®Google Scholar
• Won C, Kim BH, Yi EH, et al. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology. 2015;62(4):1160–1173. doi:10.1002/hep.27968
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang J, Shen B, et al. Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition. J Exp Clin Cancer Res. 2015;34(1):116. doi:10.1186/s13046-015-0229-3
   PubMedGoogle Scholar
• Yin Z, Ma T, Lin Y, et al. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J Cell Biochem. 2018;119(11):9419–9432. doi:10.1002/jcb.27259
   PubMed Web of Science ®Google Scholar
• Iwahasi S, Rui F, Morine Y, et al. Hepatic stellate cells contribute to the tumor malignancy of hepatocellular carcinoma through the IL-6 pathway. Anticancer Res. 2020;40(2):743–749. doi:10.21873/anticanres.14005
   PubMed Web of Science ®Google Scholar
• Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer. 1992;70(3):709–713. doi:10.1002/1097-0142(19920801)70:3<709::AID-CNCR2820700328>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27(8):1091–1097. doi:10.1111/j.1478-3231.2007.01550.x
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836–1846. doi:10.1002/hep.26338
   PubMed Web of Science ®Google Scholar
• Bağırsakçı E, Şahin E, Atabey N, Erdal E, Guerra V, Carr BI. Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma. Oncology. 2017;93(2):136–142. doi:10.1159/000471807
   PubMed Web of Science ®Google Scholar
• Okamura Y, Sugiura T, Ito T, et al. Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma. Br J Surg. 2016;103(7):891–898. doi:10.1002/bjs.10123
   PubMed Web of Science ®Google Scholar
• Lai Q, Melandro F, Larghi Laureiro Z, et al. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: a systematic review and meta-analysis. World J Gastroenterol. 2018;24(15):1658–1665. doi:10.3748/wjg.v24.i15.1658
   PubMed Web of Science ®Google Scholar
• Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 2020;26(2):599–603. doi:10.1007/s12253-019-00585-5
   PubMed Web of Science ®Google Scholar